Abstract 453: Ablation of TRPV1 Impairs Exendin-4 Induced Suppression in Renal Cytokine Release

Abstract

Impairment of function and expression of the transient receptor potential vanilloid type 1 (TRPV1) occurs in obesity and diabetes, which may aggravate inflammation and tissue injury given that the TRPV1 mediated pathway has been shown to be anti-inflammatory. Glucagon-like peptide-1 (GLP-1), an incretin hormone released in response to food intake, is capable of protecting tissues from injury, but its mechanism largely unknown. We tested the hypothesis that exendin-4 (Ex4), a GLP-1 receptor agonist, suppresses hypoxia-induced cytokine release via a TRPV1 mediated pathway. Using gene-targeted TRPV1-null mutant (TRPV1 -/- ) or wild-type (WT, C57BL/6) mice, plasma creatinine or urine lactate dehydrogenase (LDH) levels were measured 40- min after ischemia plus 3-hr reperfusion (I/R). Renal I/R increased plasma creatinine and urine LDH levels with a greater magnitude in TRPV1-/- than WT mice (creatinine, uM: WT: 99.4 ± 4.4 to TRPV1: 129.7 ± 11.9, p < 0.05; LDH, mU: WT: 132.3± 39.8 to TRPV1-/-: 178.5 ± 44.4, p < 0.05). In vitro, cytokine or chemokine secretion from renal tissues incubated either with 95% O 2 -5% CO 2 or 99% nitrogen (hypoxia) was measured. TNFα, IL-6, or MCP-1 release in response to nitrogen (1 hr) was increased in both strains with a bigger magnitude in TRPV1-/- than WT mice (p<0.05). Blockade of receptors for calcitonin gene-related peptide (CGRP) with CGRP8-38 (10 -7 M) further increased hypoxia-induced MCP-1 release in WT mice (p<0.05). Ex4 suppressed nitrogen (0.5hr)-induced cytokine/chemokine release from the kidneys in WT but not TRPV1-/-mice (WT: IL-6: 0.74 ± 0.08 to 0.66 ± 0.03; TNF-a: 0.73 ± 0.07 to 0.66 ± 0.03; MCP-1: 16.1± 3.5 to 12.7 ± 1.3 pg/g/min, p < 0.05. TRPV1-/-: p>0.05 for all). Moreover, Ex4 increased CGRP release from the renal pelvis in WT ( p < 0.05) but not TRPV1 -/- mice, which can be inhibited by Ex9-39, an Ex4 antagonist. Thus, ablation of TRPV1 or blockade of CGRP receptors enhances hypoxia-induced inflammation and renal injury following I/R. Ex4 suppresses hypoxia-induced cytokine/chemokine release and enhances CGRP release from the kidney only when TRPV1 function and expression are intact, suggesting that TRPV1/CGRP may play a key role mediating Ex4-induced anti-inflammatory effects.